Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
70.90    -1.10 (-1.53%)
Bid:
70.80
Ask:
71.00
Spread: 0.20 (0.282%)
Market Cap: £678.57m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

CEO succession

16 Apr 2024 07:00

RNS Number : 7054K
Dr. Martens PLC
16 April 2024
 

This announcement contains inside information.

 

16 April 2024

Dr. Martens plc

CEO succession

 

Dr. Martens plc ('the Company') announces that Kenny Wilson has decided that this will be his final year as Chief Executive Officer (CEO) of the Company. As part of an orderly succession plan, and following a thorough search process, the Board is delighted to announce that Ije Nwokorie, currently Chief Brand Officer (CBO), will succeed Kenny as CEO. Kenny and Ije will work together to ensure a smooth handover, with Ije becoming CEO before the end of the current financial year. Ije will remain as CBO in the meantime, with his focus being on the brand and driving demand ahead of the important AW24 season.

Paul Mason, Chair, said "Kenny's contribution to Dr. Martens has been immense. He has spear-headed a brand-first DTC-driven strategy, achieving significant growth, with pairs more than doubling during his tenure. With his focus on product, brand and custodianship he has instilled a strong culture through the organisation. I am grateful that he will ensure an orderly transition to Ije over the coming year, alongside our incoming CFO Giles Wilson."

Lynne Weedall, Senior Independent Director and Chair of the Nomination Committee, said "Ije is an inspirational leader and his experience in helping drive DTC-led growth at Apple will be highly relevant in the coming years. He knows the Company well, having been a Non-Executive Director for three years and we are already benefiting from his brand expertise since he joined as CBO in February. We are delighted that he will be the next CEO."

Kenny Wilson, CEO, said, "Dr. Martens is an incredible brand powered by our fantastic people. After six years in the role, I feel that the time is right to hand over this year, and I am excited that Ije will be my successor. I have enjoyed working with Ije, both as a Board member and in the executive leadership team in recent months, and I have seen his brand knowledge and passion first-hand. I look forward to working with him closely in the year ahead."

Ije Nwokorie, CBO, said, "I am thrilled that I will be the next CEO of Dr. Martens. We have a phenomenal brand, an excellent product range and a passionate culture. I am looking forward to working with Kenny through this transition year."

 

This announcement has been made in accordance with the requirements of 9.6.11 of the UK Listing Rules. The Company confirms that there is no further information required to be disclosed pursuant to paragraph 9.6.13 of the UK Listing Rules.

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations Bethany.Barnes@drmartens.com +44 7825 187465

Beth Callum, Investor Relations Manager Beth.Callum@drmartens.com +44 203 995 2644

 

Press

H/Advisors Maitland +44 207 379 5151

Katharine Spence +44 7384 535739

Gill Hammond, Director of Communications +44 7384 214248

 

This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of the Company is Emily Reichwald, Company Secretary.

Notes to editors

Ije Nwokorie was a Non-Executive Director on the Board from January 2021 until early 2024, when he joined the business as Chief Brand Officer, with responsibility for product, marketing and strategy. Ije was previously at Apple Inc, where he was Senior Director, Apple Retail from January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAPLSFAPLEFA
Date   Source Headline
2nd Sep 20259:30 amRNSDirector/PCA Shareholding
29th Aug 20254:22 pmRNSTotal Voting Rights
12th Aug 20253:17 pmRNSDirector/PDMR Shareholding
1st Aug 202511:51 amRNSTotal Voting Rights
28th Jul 20258:53 amRNSDirector/PDMR Shareholding
14th Jul 20253:08 pmRNSDirector/PDMR Shareholding
10th Jul 202510:58 amRNSResult of 2025 AGM
10th Jul 20257:00 amRNSAGM Trading Update
4th Jul 20251:56 pmRNSTotal Voting Rights
17th Jun 202510:00 amRNSDirector/PDMR Shareholding
17th Jun 20259:00 amRNSAnnual Financial Report
12th Jun 20254:13 pmRNSDirector/PDMR Shareholding
5th Jun 20257:00 amRNSFinal Results
2nd Jun 20252:05 pmRNSBlock listing Interim Review
30th May 202510:52 amRNSTotal Voting Rights
27th May 20258:45 amRNSDirector Declaration
14th May 20252:20 pmRNSDirector/PDMR Shareholding
1st May 20254:02 pmRNSTotal Voting Rights
16th Apr 20254:00 pmRNSDirector/PDMR Shareholding
9th Apr 20253:00 pmRNSDirector/PDMR Shareholding
31st Mar 20259:38 amRNSTotal Voting Rights
26th Mar 202510:00 amRNSDirector/PDMR Shareholding
12th Mar 20252:26 pmRNSDirector/PDMR Shareholding
28th Feb 202511:01 amRNSTotal Voting Rights
12th Feb 20254:35 pmRNSDirector/PDMR Shareholding
12th Feb 20257:00 amRNSAppointment of Non-Executive Directors
31st Jan 202510:36 amRNSTotal Voting Rights
27th Jan 20257:00 amRNSQ3 FY25 Trading Statement
15th Jan 20256:14 pmRNSDirector/PDMR Shareholding
2nd Jan 202512:02 pmRNSTotal Voting Rights
20th Dec 20243:07 pmRNSHolding(s) in Company
13th Dec 202411:54 amRNSDirector/PDMR Shareholding
12th Dec 20247:00 amRNSBlock Listing Application
2nd Dec 202410:43 amRNSBlock listing Interim Review
2nd Dec 202410:10 amRNSTotal Voting Rights
28th Nov 20247:01 amRNSConfirmation of new CEO start date
28th Nov 20247:00 amRNSHalf-year Report
12th Nov 20243:56 pmRNSDirector/PDMR Shareholding
31st Oct 20243:23 pmRNSTotal Voting Rights
15th Oct 20243:19 pmRNSDirector/PDMR Shareholding
2nd Oct 20241:55 pmRNSDirector/PDMR Shareholding
30th Sep 202410:24 amRNSTotal Voting Rights
26th Sep 20242:00 pmRNSTransaction by PCA of PDMR
25th Sep 20247:00 amRNSHolding(s) in Company
24th Sep 202410:53 amRNSDirector/PDMR Shareholding
23rd Sep 20244:31 pmRNSHolding(s) in Company
12th Sep 20243:13 pmRNSDirector/PDMR Shareholding
30th Aug 20243:19 pmRNSTotal Voting Rights
27th Aug 202411:58 amRNSDirector/PDMR Shareholding
20th Aug 20243:48 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.